Delivery Order SPE2DB22D3401-SPE2DB25FT3NS
- Not listed
- The Defense Logistics Agency awarded a $43,664.64 delivery order to AmerisourceBergen Drug Corp for NOVOSEVEN RT 5 mg vials, with an ultimate completion date of August 22, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. NOVOSEVEN RT is a recombinant activated Factor VII used primarily for hemostasis support in military and veteran healthcare settings,...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $7,277.44 for NOVOSEVEN RT 5 mg vials on September 18, 2025, with an ultimate completion date of October 9, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NOVOSEVEN RT 2 mg vials valued at $12,982.60 on January 2, 2026, with an ultimate completion date of January 26, 2026. The award is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a...
- The Defense Logistics Agency awarded a delivery order valued at $15,208.90 to AmerisourceBergen Drug Corp for NOVOSEVEN RT 2 MG vials, with completion scheduled for December 1, 2025. This firm fixed-price delivery order was awarded on November 6, 2025, without set-aside designation, utilizing open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's substantial...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitively-procured delivery order valued at approximately $51K for NOVOSEVEN RT 5 mg vials. The contract, issued by the Defense Logistics Agency under its Defense Supply Chain operations, carries a firm fixed price structure and is scheduled for completion by September 12, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency has awarded a delivery order valued at $5,772.72 to AmerisourceBergen Drug Corp for the supply of Novoseven RT 2 mg vials. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply agreement extending through December 2026. The delivery order is scheduled for completion by August 15, 2025, with fulfillment...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $12,167.12 for NOVOSEVEN RT 2 mg vials, a pharmaceutical product used primarily for hemophilia treatment and bleeding disorder management. The award was issued by the Defense Logistics Agency on November 10, 2025, with an ultimate completion date of December 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $21.8K firm fixed-price delivery order to AmerisourceBergen Drug Corp for NOVOSEVEN RT 5 MG vials, with an ultimate completion date of September 22, 2025. This award represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The ordering activity, based in Conshohocken, Pennsylvania, serves as the primary pharmaceutical distributor for federal...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The $82,935.48 firm-fixed-price contract is for the supply of NovoSeven RT 5 mg vials, a pharmaceutical product. The contract has an ultimate completion date of August 5, 2024. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The $27,604.30 order is for the supply of NOVOSEVEN RT 2 MG VIALS, a specialized pharmaceutical product. The delivery order is part of Amerisourcebergen's existing indefinite delivery contract with DLA to provide pharmaceuticals and medical supplies in support of military treatment programs and...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT3NSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,277.44 to AmerisourceBergen Drug Corp for NOVOSEVEN RT 5 mg vials, with completion required by May 30, 2025. This non-set-aside, firm fixed-price contract was awarded competitively on May 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. NOVOSEVEN RT is a recombinant activated Factor VII used in treating bleeding disorders, representing a specialized pharmaceutical product critical to military and veteran healthcare operations. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and extending through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's contract portfolio with the Defense Logistics Agency demonstrates its established capability to fulfill federal medical procurement requirements across multiple therapeutic domains and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 5/8/25 |